Maywufa Company Ltd. (1731.TW)
TWD 21.9
(1.62%)
TWD 21.9
(1.62%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.83 Billion TWD | 11.94% |
| 2022 | 2.52 Billion TWD | -6.04% |
| 2021 | 2.69 Billion TWD | 8.73% |
| 2020 | 2.47 Billion TWD | -9.47% |
| 2019 | 2.73 Billion TWD | 2.33% |
| 2018 | 2.67 Billion TWD | 0.85% |
| 2017 | 2.65 Billion TWD | 2.03% |
| 2016 | 2.59 Billion TWD | -1.23% |
| 2015 | 2.63 Billion TWD | 4.39% |
| 2014 | 2.51 Billion TWD | -1.69% |
| 2013 | 2.56 Billion TWD | 2.48% |
| 2012 | 2.5 Billion TWD | 1.76% |
| 2011 | 2.45 Billion TWD | -13.62% |
| 2010 | 2.84 Billion TWD | 0.76% |
| 2009 | 2.82 Billion TWD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 3.12 Billion TWD | 2.77% |
| 2024 Q1 | 3.04 Billion TWD | 7.5% |
| 2023 FY | 2.83 Billion TWD | 11.94% |
| 2023 Q1 | 2.67 Billion TWD | 5.75% |
| 2023 Q2 | 2.74 Billion TWD | 2.74% |
| 2023 Q4 | 2.83 Billion TWD | 2.18% |
| 2023 Q3 | 2.77 Billion TWD | 0.83% |
| 2022 Q3 | 2.39 Billion TWD | 0.35% |
| 2022 Q2 | 2.38 Billion TWD | -11.51% |
| 2022 FY | 2.52 Billion TWD | -6.04% |
| 2022 Q4 | 2.52 Billion TWD | 5.76% |
| 2022 Q1 | 2.69 Billion TWD | 0.05% |
| 2021 Q1 | 2.57 Billion TWD | 3.91% |
| 2021 FY | 2.69 Billion TWD | 8.73% |
| 2021 Q2 | 2.68 Billion TWD | 4.18% |
| 2021 Q4 | 2.69 Billion TWD | 3.36% |
| 2021 Q3 | 2.6 Billion TWD | -2.83% |
| 2020 FY | 2.47 Billion TWD | -9.47% |
| 2020 Q1 | 2.34 Billion TWD | -14.44% |
| 2020 Q2 | 2.42 Billion TWD | 3.54% |
| 2020 Q3 | 2.43 Billion TWD | 0.61% |
| 2020 Q4 | 2.47 Billion TWD | 1.59% |
| 2019 Q1 | 2.67 Billion TWD | 0.21% |
| 2019 FY | 2.73 Billion TWD | 2.33% |
| 2019 Q2 | 2.76 Billion TWD | 3.34% |
| 2019 Q4 | 2.73 Billion TWD | 1.78% |
| 2019 Q3 | 2.68 Billion TWD | -2.92% |
| 2018 Q4 | 2.67 Billion TWD | -2.41% |
| 2018 Q1 | 2.83 Billion TWD | 6.87% |
| 2018 Q2 | 2.84 Billion TWD | 0.52% |
| 2018 Q3 | 2.73 Billion TWD | -3.81% |
| 2018 FY | 2.67 Billion TWD | 0.85% |
| 2017 Q1 | 2.57 Billion TWD | -0.84% |
| 2017 FY | 2.65 Billion TWD | 2.03% |
| 2017 Q4 | 2.65 Billion TWD | -0.36% |
| 2017 Q3 | 2.65 Billion TWD | 0.64% |
| 2017 Q2 | 2.64 Billion TWD | 2.61% |
| 2016 Q2 | 2.55 Billion TWD | -0.04% |
| 2016 Q1 | 2.55 Billion TWD | -2.9% |
| 2016 FY | 2.59 Billion TWD | -1.23% |
| 2016 Q4 | 2.59 Billion TWD | 3.01% |
| 2016 Q3 | 2.52 Billion TWD | -1.22% |
| 2015 Q4 | 2.63 Billion TWD | 0.96% |
| 2015 FY | 2.63 Billion TWD | 4.39% |
| 2015 Q2 | 2.6 Billion TWD | 0.51% |
| 2015 Q3 | 2.6 Billion TWD | -0.17% |
| 2015 Q1 | 2.59 Billion TWD | 3.04% |
| 2014 Q3 | 2.46 Billion TWD | -3.25% |
| 2014 Q2 | 2.55 Billion TWD | -2.57% |
| 2014 FY | 2.51 Billion TWD | -1.69% |
| 2014 Q1 | 2.61 Billion TWD | 2.23% |
| 2014 Q4 | 2.51 Billion TWD | 2.02% |
| 2013 Q3 | 2.59 Billion TWD | 1.75% |
| 2013 Q4 | 2.56 Billion TWD | -1.17% |
| 2013 FY | 2.56 Billion TWD | 2.48% |
| 2013 Q1 | 2.46 Billion TWD | -1.51% |
| 2013 Q2 | 2.54 Billion TWD | 3.48% |
| 2012 Q1 | 2.47 Billion TWD | 0.66% |
| 2012 Q3 | 2.46 Billion TWD | -1.67% |
| 2012 Q4 | 2.5 Billion TWD | 1.57% |
| 2012 FY | 2.5 Billion TWD | 1.76% |
| 2012 Q2 | 2.5 Billion TWD | 1.22% |
| 2011 Q4 | 2.45 Billion TWD | -2.5% |
| 2011 FY | 2.45 Billion TWD | -13.62% |
| 2011 Q1 | 2.64 Billion TWD | -6.9% |
| 2011 Q3 | 2.52 Billion TWD | -3.28% |
| 2011 Q2 | 2.6 Billion TWD | -1.62% |
| 2010 Q4 | 2.84 Billion TWD | 0.0% |
| 2010 FY | 2.84 Billion TWD | 0.76% |
| 2009 FY | 2.82 Billion TWD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Grape King Bio Ltd | 15.51 Billion TWD | 81.743% |
| Standard Chem & Pharm CO., LTD. | 11.18 Billion TWD | 74.688% |
| ScinoPharm Taiwan, Ltd. | 11.72 Billion TWD | 75.839% |
| Lotus Pharmaceutical Co., Ltd. | 32.99 Billion TWD | 91.416% |
| LIWANLI Innovation Co., Ltd. | 834.17 Million TWD | -239.506% |
| YungShin Global Holding Corporation | 11.51 Billion TWD | 75.4% |
| PhytoHealth Corporation | 2.35 Billion TWD | -20.487% |
| SCI Pharmtech, Inc. | 6.69 Billion TWD | 57.672% |
| Formosa Laboratories, Inc. | 13.63 Billion TWD | 79.231% |
| PharmaEssentia Corporation | 27.26 Billion TWD | 89.614% |
| Bora Pharmaceuticals Co., LTD. | 25.05 Billion TWD | 88.695% |